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Abstract
TGF-b1 is overexpressed in wound repair and in most proliferative disorders including benign prostatic hyperplasia and
prostate cancer. The stromal microenvironment at these sites is reactive and typified by altered phenotype, matrix
deposition, inflammatory responses, and alterations in nerve density and biology. TGF-b1 is known to modulate several
stromal responses; however there are few transgenic models to study its integrated biology. To address the actions of TGF-
b1 in prostate disorders, we targeted expression of an epitope tagged and constitutively active TGF-b1 via the enhanced
probasin promoter to the murine prostate gland epithelium. Transgenic mice developed age-dependent lesions leading to
severe, yet focal attenuation of epithelium, and a discontinuous basal lamina. These changes were associated with elevated
fibroplasia and frequency of collagenous micronodules in collapsed acini, along with an induced inflammation in nerve
ganglia and small vessels. Elevated recruitment of CD115+ myeloid cells but not mature macrophages was observed in
nerve ganglia, also in an age-dependent manner. Similar phenotypic changes were observed using a human prostate
epithelium tissue recombination xenograft model, where epithelial cells engineered to overexpress TGF-b1 induced fibrosis
and altered matrix deposition concurrent with inflammation in the stromal compartment. Together, these data suggest that
elevated TGF-b1 expression induces a fibroplasia stromal response associated with breach of epithelial wall structure and
inflammatory involvement of nerve ganglia and vessels. The novel findings of ganglia and vessel inflammation associated
with formation of collagenous micronodules in collapsed acini is important as each of these are observed in human prostate
carcinoma and may play a role in disease progression.
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Introduction
A reactive stroma microenvironment is observed in wound
repair, fibrosis, and in most proliferative diseases, including prostate
cancer and benign prostatic hyperplasia. The activation of stromal
cell proliferation and biology in wound repair facilitates granulation
tissue formation and tissue remodeling through ECM deposition
and growth factor production [1,2]. This generalized reactive
stroma response is adaptive and functions to preserve tissue integrity
and homeostasis. Our earlier studies have shown that reactive
stroma initiates at foci of early premalignant prostatic intraepithelial
neoplasia (PIN) in human prostate gland and co-evolves with the
development of carcinoma and expression of transforming growth
factor beta 1 (TGF-b1) in PIN epithelium [3,4]. Similarly, reactive
stroma initiates at sites of benign prostatic hyperplasia and is
associated focally with overexpression of IL-8 [5]. In vivo modeling
studies have shown that reactive stroma promotes angiogenesis and
prostate cancer progression as well as proliferative responses in
normal human prostate epithelial cells, although little is understood
about the specific mechanisms of reactive stroma formation [6,7,8].
Several growth factors have been identified as regulators of the
reactive stroma microenvironment. Among these, TGF-b1 has
emerged as being instrumental in both its direct and indirect effects
on several pathways that mediate rapid host immune cell
modulation and matrix remodeling.
TGF-b1 is a key factor released by platelets at sites of wound
repair and modulates angiogenesis and inflammatory responses.
The expression of TGF-b1 is elevated in most carcinomas and
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prostate cancer and prostatitis [9,10,11,12]. Moreover, each of
these disorders is associated with inflammation. TGF-b1 can affect
several pathways known to mediate rapid host immune cell
modulation, stromal biology and matrix remodeling through
cytostatic, chemotactic, and fibrotic induction of different cell
populations unique to stroma. However, few studies have
addressed these biological responses in vivo using expression of
active TGF-b1 in transgenic mice. Targeted overexpression in the
liver in a murine transgenic model led to the development of
severe cirrhosis and glomerulonephritis [13,14]. Furthermore,
targeted expression in the pancreas induced pancreatitis, whereas
expression in the salivary gland resulted in glandular fibrosis and
acinar atrophy [15,16]. Overexpression of TGF-b1 in a murine
MMTV model of mammary cancer demonstrated marked
suppression of tumor formation [17]. However, our studies with
human xenograft models have shown that TGF-b1 promotes
reactive stroma formation and prostate cancer progression
[18,19]. In addition, our previous in vitro studies have demonstrat-
ed that TGF-b1 modulates differentiation of normal prostate
stromal cells into myofibroblasts, a cell type that is unique to
tissues undergoing fibrosis, remodeling, or reactive stroma
formation in several disorders [4].
Accordingly, TGF-b1 is emerging as a potential target of
therapeutics in modulating fibrosis, inflammation, and tumor
progression. It is clear that the pleiotropic nature of TGF-b action
is due in part to the local cell and tissue-specific milieu. Therefore,
we sought to address the potential etiological role of aberrant
TGF-b1 action in inducing stromal microenvironment responses
in normal intact murine prostate gland tissue. We report here a
transgenic mouse model constructed with epitope tagged and
constitutively active TGF-b1 expressed in the prostate gland
epithelium. In addition, we have evaluated a tissue recombination
model generated with human prostate epithelial cells engineered
to overexpress active TGF-b1 and stromal cells in xenografts.
Results reported here demonstrate that expression of constitutively
active TGF-b1 results in age-dependent phenotypic alterations
characterized by attenuation of secretory acini walls, induction of
fibroplasia, and inflammation in vessels and nerve ganglia. We also
report the formation of unique fibrotic collagenous micronodules,
shown previously to be associated with human prostate cancer.
Materials and Methods
Ethics Statement
All animals were handled in strict accordance with good animal
practice as defined by the relevant national and institutional
animal welfare bodies, and all animal work was approved by
IACUC protocol AN-1867.
Transgenic construction
The composite probasin promoter ARR2PB (provided by Dr.
Robert J. Matusik) was used to target transgene expression
specifically to murine prostate epithelium as reported previously
[8,20,21]. ARR2PB was cloned 41 bp upstream of the HA-tagged
TGF-b1(a) insert in the pEF6 vector (Courtesy of Dr. Larry
Wolfraim, NCI, NIH) that also contained a 39 BGH polyA tail
[22]. The resulting 2.7 kB ARR2PB-HA-TGF-b1(a) DNA frag-
ment was excised, gel purified, and provided to the Baylor
Genetically Engineered Mouse Core for microinjection into
C57BL/6 mouse egg pronuclei. The HA-TGF-b1(a) insert was
also excised from pEF6 and cloned into the pBMN-IRES-eGFP
retroviral vector, packaged and virus used to transduce LNCaP
human prostate carcinoma cells and NHPrE1.2 human prostate
epithelial cells as reported previously [19,23]. Expression of full
length HA-TGF-b1(a) protein in conditioned media was verified
by Western blot to HA epitope and ELISA to TGF-b1 (data not
shown).
PCR amplification of tail-derived genomic DNA was used to
identify transgenic mice. Primers designed to amplify a 1.2 kb
region of transgene encompassing a region upstream of the start
codon to the internal HA tag were as follows: 59 CAG-
TGTGGTGGAATTGCCCTTATCTGGTACC and 59CAGA-
GATGCTAGTCTGGCACGTCGTATGGGTAGCT. Amplifi-
cation of MbCx7 served as an internal positive control using the
following primers: 59 GATGTGCTCCAGGCTAAAGTT and 59
AGAAACGGAATGTTGTGGAGT. PCR reactions used Plati-
num Taq DNA polymerase (Invitrogen) and 2 mM MgCl2 for 32
cycles at a 55uC annealing temperature for 1 min. Five founder
mice were transgenic and bred for examination of F1 generation.
Screening of F1 mice revealed that four founders exhibited
germline transmission.
Animal husbandry
All housing and manipulations of mice followed an approved
IACUC protocol (AN-1867). Male and female mice from the F1
generation were bred with wild-type mates and resulting F2
generation males were screened by PCR of genomic tail DNA.
Wildtype and transgenic littermates from each line were examined
for RNA production by RT-PCR. Primers designed to amplify a
region encompassing the internal HA tag were as follows:
59ATACCAACAGCTACCCATACGACG and 59 CACTTC-
CAGCCCAGGTCC. GAPDH primers designed to anneal to
endogenous genetic material were as follows: 59 CCTACCCC-
CAATGTGTCCG and 59 CCTTCTTGATGTCATCATAC-
TTGGC. Reverse transcription was performed at 50uC for
30 min followed by PCR amplification for 28 cycles at a 60uC
annealing temperature for 1 min.
Cell lines
LNCaP human prostate carcinoma cells were acquired from
ATCC (American Type Culture Collection, Manassas, VA) and
maintained in RPMI 1640 media (Invitrogen, Carlsbad, CA)
supplemented with 10% fetal bovine serum (FBS) (Hyclone,
Logan, UT), 100 units/ml penicillin, and 100 mg/ml streptomycin
(Sigma, St Louis, MO). The Phoenix A packaging cell line was
purchased from ATCC and maintained in DMEM with high
glucose (Invitrogen) supplemented with 10% heat inactivated FBS
(Hyclone), 2 mM glutamine (Invitrogen), 100 units/ml penicillin,
and 100 mg/ml streptomycin (Sigma). The C57BL/6 mouse
prostate stromal cell line was generated as reported previously
[19].
To engineer cell lines, primers were designed to amplify cDNA
from the pEF6-HA-pTGFb1(a) vector for cloning into the
multicloning site of the pBMN-Ires-eGFP retroviral vector
(courtesy of Dr. Gary Nolan). Sequences were verified to confirm
construct fidelity and pBMN-HA-TGF-b1(a)-IRES-eGFP was
then transfected into Phoenix A cells with a Calcium Phosphate
Transfection kit (Invitrogen) for retroviral engineering of the
NHPrE1.2 human prostate epithelial [24] and LNCaP cell lines.
Virus was collected, filtered through 0.45 mm and applied to infect
cells as described previously [19]. Infected cells were subsequently
FACS sorted by GFP expression.
Kidney capsule xenografts
Tissue recombination was performed as described previously
[24]. Briefly, urogenital mesenchyme was dissected from 18dpc rat
pups and recombined with 6610
5 NHPrE1.2 cells (engineered for
TGF-Beta Transgenic Mouse
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plugs were then grafted under the kidney capsule of SCID mice for
8 or 12 weeks and removed for formaldehyde fixation and paraffin
embedding. Sections were cut at 5-micron thickness for immuno-
staining.
Immunohistochemistry
The intact urogenital tract including the bladder, seminal
vesicle and prostate gland was removed en mass, fixed in 4%
paraformaldehyde and processed for histology and immunohisto-
chemistry as we have reported previously [8]. For initial
orientation and evaluation of phenotype, 25 serial sections were
generated and sections 8 and 16 were stained with hematoxylin
and eosin (H&E). All immunostaining was performed on adjacent
serial sections with the MicroProbe Staining System (Fisher
Scientific), and counterstained with hematoxylin as described
previously [4,8]. To validate protein expression by transgene in
murine ventral prostate epithelia via the HA epitope tag, sections
from a cohort of transgenic and control mice were subjected to
enzymatic antigen retrieval done by incubation in 0.1% pronase
(Calbiochem) at 50uC for 3 min followed by blocking with goat
serum (5%) for 30 min at RT. IHC was performed with rabbit
anti-HA (1:100, Santa Cruz, sc-805) overnight at 4uC, followed by
biotin-conjugated goat anti-rabbit secondary antibody (1:500,
Molecular Probes, D-20691) for 1 hr at 37uC. For tenascin-C
immunostaining, representative tissue was subjected to pronase
antigen retrieval as described above, followed by a rabbit anti-
tenascin-C antibody (1:50, Chemicon, AB19013) overnight at 4uC
and secondary antibody as described above for anti-HA. All other
IHC was performed on representative tissues subjected to heat-
mediated citrate (pH 6) antigen retrieval followed by blocking with
goat serum (5%) for 30 min at RT. Primary antibodies were rabbit
anti-CD115 (1:50, Abcam, ab61137); rat anti-F4/80 (1:100,
Abcam, ab6640); rabbit anti-collagen type IV (1:500, Abcam,
ab19808); and rabbit anti-p65 (1:200, Santa Cruz, sc-109). Each
was incubated overnight at 4uC, followed by biotin-conjugated,
goat-anti-rabbit secondary antibody (1:500, Molecular Probes, D-
20691) or biotin-conjugated, goat-anti-rat secondary antibody
(1:500, Molecular Probes, D-20697) for 1 hr at 37uC. Primary
antibodies for IHC on tissue recombinants were rat anti-F4/80
(1:200, Serotec, MCA497GA) and rabbit anti-p65 (1:200, Santa
Cruz, sc-109). Sections were incubated overnight at 4uC, followed
by biotin-conjugated, goat-anti-rat (1:200, Zymed, 81-9540) or
swine-anti-rabbit (1:200, Dako, E0353) secondary antibodies,
respectively.
Evaluation of tissue phenotype
Ventral prostate and surrounding regions were evaluated as the
initial focus of this analysis due to the well-characterized simple
epithelial acini histology and stroma of this prostate lobe. Tissues
from each respective transgenic line were evaluated separately and
data grouped together for comparison with wild-type littermates.
Phenotypic changes in inflammatory foci, epithelial wall attenu-
ation (thinning), and stromal fibroplasia were each evaluated as
separate histopathologic parameters using a semi-quantitative
protocol similar to what we have reported previously [25]. H&E
sections (section number 8 and 16) of prostate tissue from all mice
listed in Table 1 (n=41 transgenic mice, n=38 control mice) were
imaged (2006 and 4006 fields) and graded for each parameter
separately according the following pathologic scale: 0=wild-type
phenotype; 1=minor phenotypic involvement (non-wildtype
histology and minor involvement in less than 10% of the tissue
or region being evaluated); 2=moderate phenotypic involvement
(moderate involvement in 10–50% of the tissue or region being
evaluated); 3=severe phenotypic involvement (major involvement
in .50% of the tissue or region being evaluated). Inflammatory
foci were defined as focal sites of accumulation of lymphocytes and
granulocytes. Epithelial wall attenuation was defined as epithelial
walls thinned to less than 50% of wild type epithelial height.
Fibroplasia was defined as foci of stromal hyperplasia following
standard pathological criteria and accumulation of prototypical
reactive stroma. Values were averaged for wildtype and transgenic
mice and divided into categories of less than 1 year and greater
than 1 year of age.
Statistical evaluation
Mann-Whitney and non-parametric Student’s t-tests were used
to assess significant differences for each measured phenotype.
Significance of the frequency of collagenous micronodules was
evaluated using Fisher’s exact test. For quantitative evaluation of
CD115 and F4/80 staining, positive cells were counted manually
in the nerve ganglia in a blinded study (reviewer blinded to the
mouse genotype). Values were averaged for each mouse and
Kruskal-Wallis non-parametric ANOVA and Mann-Whitney tests
were used to determine significance. For all tests, data generating a
P value less than 0.05 was considered statistically significant. All
analyses were performed using the Prism statistical software
package.
Results
Targeted HA-TGF-b1(a) Expression to Mouse Prostate
Gland
Expression of constitutively active TGF-b transgene was
targeted to epithelial cells of the male urogenital tract in order
to assess TGF-b1 actions on the stromal environment. An HA-
TGF-b1(a) construct was used containing mutations in Cys223
and Cys225 to provide constitutive biological activity and an
internal HA epitope tag as previously reported [22]. To verify
biological activity of recombinant protein expressed from this
construct, prostate epithelial cells in vitro were engineered to
express HA-TGF-b1(a) construct. Expression and secretion of full-
length protein was confirmed by Western blot (HA epitope) and
ELISA for TGF-b1 protein (data not shown). Biological activity of
secreted protein was confirmed via induction of phenotypic
changes in C57BL/6 murine prostate stromal cells as we have
reported previously [23]. To target expression in transgenic mice,
the murine enhanced probasin promoter (ARR2PB) was used to
drive HA-TGF-b1(a) expression in the prostate gland [20]. Four
lines of transgenic mice were confirmed by PCR screening tail
DNA for genomic integration (Figure 1A). Transgene mRNA was
detected in the prostate gland of all four lines with three of the four
transgenic lines exhibiting higher levels (Figure 1B). Transgenic
mice exhibited no apparent alterations in development of
urogenital tract or reproductive potential relative to control mice.
Table 1. Timepoints of phenotype analysis.





(n=number of transgenic and wild-type animals evaluated in each age range).
doi:10.1371/journal.pone.0013751.t001
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transgenic lines and control littermate mice from 12 weeks to 144
weeks of age (n=38 control and n=41 transgenic mice) as
outlined in Table 1. HA-TGF-b1(a) protein was expressed in a
focal manner in the ventral, dorsal, and lateral prostate gland as
shown in Figure 1D. Age-matched wild-type mice showed no
specific immunoreactivity for HA epitope tag (Figure 1C). As
expected, focal expression of HA-TGF-b1(a) was particularly
evident in the ventral prostate lobe in transgenic mice owing to the
efficacy of ARR2PB induced expression in this region of murine
prostate gland. All transgenic lines exhibited similar phenotypic
changes in epithelium and stroma.
Expression of HA-TGF-b1(a) induces an age-dependent
attenuation in epithelial acini wall integrity
Initial analyses suggested an alteration in the epithelial wall
integrity in transgenic mice as compared with control mice
(Figure 2). Some acini exhibited foci of attenuated epithelium,
evident as diminished cell height and acinar wall thickness in mice
as early as 19 weeks of age (Figure 2B). In some foci, epithelium
exhibited a flattened, near squamous morphology (Figure 2D).
Consistent with this, a more irregular spacing pattern and density
of nuclei in the epithelial wall was initially observed at 30 weeks of
age. These changes were associated with a higher frequency of
pyknotic intraluminal cells in transgenic mice, suggesting cell
apoptosis (Figure 2H). Of interest, the severity and frequency of
this response was particularly apparent in transgenic mice over a
year of age (Figures 2D and 2F). In contrast, acinar walls in control
mice exhibited a prototypical cuboidal epithelium with a
continuous epithelial height and regular linear spacing of nuclei
at all ages examined (Figures 2A and 2C). Alteration in acini wall
thickness was associated with focal discontinuity and thinning in
the basal lamina as shown by IHC for basal lamina collagen IV
(Figures 2E and 2F). In addition, IHC for the HA epitope tag
showed that focal expression of transgene could be observed in
spatial association with regions of attenuated epithelial wall acini
(Figure 2G). Quantitation of changes in epithelial acini wall
thickness demonstrated significant differences in transgenic mice
over a year of age compared to aged wildtype controls (Figure 2I).
Expression of HA-TGF-b1(a) in prostate epithelia induces
an inflammatory response
Concomitant with alterations in epithelial wall integrity,
transgenic mice also exhibited focal regions of inflammation in
the vasculature and local parasympathetic ganglia. Vascular
fibroplasia typified by a thickened tunica media in intermediate
vessels was noted in some transgenic mice and was usually
associated with inflammation in the vessel wall (Figure 3A). Foci of
inflammation were also observed adjacent to vessels beginning at
34 weeks in transgenic mice (Figure 3B). Of interest, the most
highly penetrant phenotype in transgenic mice was inflammation
in the nerve ganglia associated with interlobular neurovascular
bundles in transgenic mice over a year of age (Figures 3C and 3D).
Nearly all ganglia in this cohort of transgenic mice were infiltrated
Figure 1. HA-TGF-b1(a) transgenic expression. Panel A. Representative genomic DNA PCR screen of transgenic litters demonstrating germline
transmission. Panel B. RT-PCR for transgene message in the prostate gland. GAPDH amplification serves as an internal control. Panel D. IHC of
transgene demonstrates focal expression in ventral, lateral, and dorsolateral regions of secretory acini. Panel C. Wildtype acini demonstrate no
immunoreactivity to HA epitope. Images C and D were captured at 6200 magnification.
doi:10.1371/journal.pone.0013751.g001
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exhibited little inflammation in ganglia. Similar to patterns of acini
wall attenuation, independent grading showed significant increases
in inflammation of the vessels and ganglia in transgenic mice over
52 weeks of age compared to either age-matched wildtype mice or
to mice under one year of age (Figures 3E and 3F).
Expression of HA-TGF-b1(a) in prostate epithelia induces
focal fibroplasia and nodular stromal lesions
Fibroplasia was observed in inter-acinar regions in transgenic
mice. Similar to other phenotypic observations, the appearance of
inter-acinar stromal fibroplasia was evident in transgenic mice
over a year of age and consisted of more focal rather than
Figure 3. Inflammation is increased in an age-dependent manner in nerve ganglia and associated vasculature of TGF-b1 transgenic
mice. Panel A. Vascular fibroplasia is evident in the wall of some vessels. Panel B. Focal regions of inflammation characterized by accumulations of
immune cells is observed adjacent to some vessels in an age-dependent manner. Panel C and D. Peripheral inflammation appears within most
prostatic interlobar parasympathetic ganglia and neurovascular bundles in transgenic mice. Panels E and F. Quantitation yields significantly greater
inflammation in aged transgenic compared to wild-type vessels and ganglia, respectively (P,0.05). All images captured at 6200 magnification.
doi:10.1371/journal.pone.0013751.g003
Figure 2. Expression of HA- TGF-b1(a) results in attenuation of prostate gland secretory epithelium. Panels A and C. Representative
micrographs of wild-type ventral prostate from 30-week and 62-week old mice, respectively. Micrographs shown are representative of all ages
examined. Panel B. Overexpression of TGF-b1 results in thinning and denuding of the epithelial wall in a 29-week old transgenic mouse. Panel D.
Ventral prostate from 62-week old transgenic mouse demonstrates severe attenuation. Panel F. IHC for collagen type IV demonstrates discontinuity
of basement membrane in transgenic compared to wild-type (Panel E) prostate. Panel G. HA immunolocalization is observed in some areas of wall
attenuation in transgenic mice. Panel H. Pyknotic appearing cells are evident in the lumen of acini in transgenic mice. Panel I. Quantitation of
epithelial attenuation yields significantly greater thinning in aged transgenic compared to wild-type ventral prostate gland (P,0.05). Images A–F and
H captured at 6200 magnification. Image G captured at 6400 magnification.
doi:10.1371/journal.pone.0013751.g002
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the stroma adjacent to acini exhibited a reactive phenotype
associated with elevated deposition of tenascin-C (Figure 4B), a
prototypical marker of reactive stroma in the prostate gland as we
have reported previously [4,5]. Some areas of fibroplasia appeared
nodular with lamellar deposition of tenascin-C at the base and
stalk as well as the periphery of the nodules that extend into the
acini lumen (Figures 4D and 4E). The matrix of these stromal
nodules was positive in Masson’s trichrome (Figure 4F) indicating
a deposition of collagen fibrils typically associated with wound
repair and fibrosis. The lesions were also similar in histopathology
to collagenous micronodules described in human prostate cancer
and extended into collapsed glandular acini with attenuated
epithelium (Figures 5A–5G). A significant increase in general
fibroplasia was noted in mice over a year of age and was
significantly higher in transgenic mice as compared to age-
matched control mice (Figure 5H). Moreover, transgenic mice
exhibited a significant increase in the frequency of the collagenous
micronodules as compared to wild type littermates.
Expression of HA-TGF-b1(a) induces elevated recruitment
of monocytes
Consistent with age-associated inflammatory changes, trans-
genic mice exhibited differential immunoreactivity of CD115+
myeloid cells in the neurovascular bundles and ganglia compared
to wild-type littermates (Figures 6A and 6B). Quantitation revealed
a significant increase in the recruitment of CD115+ myeloid cells
to nerve ganglia of aged transgenic mice compared to wildtype
(Figure 6C). Interestingly, IHC for F4/80 positive macrophages
suggested altered immunoreactivity in neurovascular bundles of
both wildtype and transgenic mice over one year of age, however
quantitation of this trend did not yield statistical significance
(Figure 6D). Similarly, there were no significant quantitative
changes in either the monocyte or mature macrophage popula-
tions within the general stroma of the ventral prostate lobe proper
(data not shown).
Expression of HA-TGF-b1(a) in prostate tissue
recombinants produces a fibroplasia phenotype
To address HA-TGF-b1(a) in a human epithelium/rodent
stroma recombinant model and to further address induced stromal
fibroplasia, normal human prostate NHPrE1.2 epithelial cells were
engineered to express HA-TGF-b1(a). Control NHPrE1.2 and
HA-TGF-b1(a) expressing NHPrE1.2
TGFb cell lines were recom-
bined with rat urogenital mesenchyme (rUGM) and placed under
the kidney capsule of SCID mice for 8 or 12 weeks. Tissue
recombinants constructed with HA-TGF-b1(a) expressing cells
demonstrated a decrease in overall graft size over both time
periods (Figure 7A). Both control and experimental recombinants
showed that UGM induced NHPrE1.2 cells to differentiate to
glandular epithelial acini with associated stroma (Figures 7B and
7C). Compared to controls, however, 8-week tissue recombinants
made with HA-TGF-b1(a) expressing NHPrE1.2 cells showed
demonstrable increases in collagen deposition, evident by
trichrome staining (Figures 7B and 7C) and elevated macrophage
infiltration (Figures 7D and 7E). Immunohistochemistry for the
p65 subunit of NF-kB corroborated the presence of a macro-
phage-rich inflammatory infiltrate. Control tissue exhibited
essentially no nuclear p65 immunoreactivity (Figure 7F), whereas
an increase of p65 activation in both epithelia and a subset of
stroma was observed in recombinants made with HA-TGF-b1(a)
expressing epithelial cells (Figure 7G). Compared to controls
(Figure 7H), 12-week recombinants were either very small or
showed severe attenuation of glandular architecture and very
limited numbers of attenuated acini (Figure 7I). Accordingly, HA-
TGF-b1(a) expression in human prostate progenitor epithelia in
Figure 4. Fibroplasia in transgenic mice exhibits markers of reactive stroma. Serial sections showing stromal thickening (Panel A, arrow)
with increased deposition of tenascin-C (Panel B, IHC for tenascin-C), consistent with a reactive stroma phenotype in areas surrounding some
attenuated epithelial acini. Panel C. Tenascin-C immunoreactivity is also deposited near the base of stromal micronodules. Panel D and E. Tenascin-C
deposition appears to form lamellar layers near the base and periphery of stromal micronodules. Panel F. Masson’s trichrome staining indicates
nodules are composed of collagen (blue). Images A–D & F were captured at 6200 and image E at 6400 magnification.
doi:10.1371/journal.pone.0013751.g004
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consistent with the increases in collagen deposition, inflammatory
cell infiltration, and glandular attenuation observed in the HA-
TGF-b1(a) transgenic animals.
Discussion
Data presented here shows that targeted expression of
constitutively active TGF-b1 in prostate gland epithelium resulted
in focal expression of the transgene that was associated with
attenuation and breakdown of the glandular acini wall epithelium,
degeneration of secretory acini, inflammation of vessels and nerve
ganglia, and an induced stromal fibroplasia. Of interest, these
phenotypes evolved as an age-dependent process with significant
differences observed in mice over a year of age. The earliest focal
phenotype was an attenuation of epithelial cells in acini walls,
concomitant with a degeneration of basal lamina integrity in some
but not all acini wall regions. Inflammatory and fibroplasia
alterations appeared to be secondary to this focal epithelial
attenuation. The appearance of pyknotic nuclei in conjunction
with focal regions of severe epithelial wall thinning suggested cell
damage. Over time, this process of epithelial disruption would be
expected to generate a physical breach in the basement membrane
thereby providing a gateway of entry for constitutively active
TGF-b1 to enter the stromal compartment. Indeed, collagen IV
immunohistochemistry showed focal regions of discontinuity in the
basal lamina surrounding several ventral prostatic acini in
transgenic mice. This is a key alteration in homeostasis since the
stroma is normally restricted from access to proteins secreted by
epithelium into the lumen within glandular tissues. Such an
alteration would also be expected to generate host responses in the
stromal compartment. As TGF-b1 is a potent inducer of reactive
stroma, it is likely that a repair response was induced by active
HA-TGF-b1(a) subsequent to release from damaged acini and loss
of the epithelium integrity. This defect is conceivably more
pronounced in mice over one year of age owing to both the natural
aging processes and TGF-b1-induced accumulated defects in
epithelial wall integrity. Our previous reports have shown that
reactive stroma initiates adjacent to preneoplastic prostatic
intraepithelial neoplasia (PIN) lesions in a heterogeneous pattern
where epithelial cells had lost polarity, suggesting defects in acini
wall integrity [4]. This study also showed that overexpression of
TGF-b1 was first noted in a heterogeneous focal pattern during
the evolution of PIN. Data reported here suggests that both the
overexpression of TGF-b1 together with the loss in epithelial
polarity in PIN results in a focal induction of reactive stroma.
These observations are critical to understanding the role of the
microenvironment in the clinical progression of prostate cancer.
We have shown previously that reactive stroma promotes prostate
cancer progression via induction of angiogenesis and the
downstream actions of TGF-b1 induced factors in reactive stroma
including connective tissue growth factor (CTGF) and fibroblast
growth factor 2 (FGF-2) [6,18,19]. Moreover, we have reported
previously that patients with high grade reactive stroma, exhibit a
significantly reduced time to biochemical recurrent disease as
evidenced by rise in serum PSA levels [25].
A novel finding in this study was inflammation associated
primarily with the neurovascular bundles and local ganglia
Figure 5. Collagenous micronodules in TGF-b1 transgenic mice. Panel A. Micronodules originate from the stroma immediately adjacent to
epithelial acini (asterisk). Panel B. Micronodules are associated with a fibroplastic reactive stroma at their base (arrows) and project into the wall of
epithelial acini. Panel C. Periacinar stroma is thickened in regions adjacent to micronodules. Vessels are often observed at the base of stromal
micronodules (arrow). Panel D and E. Larger stromal nodules show greater deposition of matrix and project fully into the lumen of collapsed atrophic
acini. Panel F. In certain cases, a collagenous micronodule (asterisk) appears adjacent to regions of transgene expression in the epithelial layer
(arrowheads: IHC for HA epitope). Panel G. Focal immunoreactivity for HA epitope can be observed in epithelium adjacent to regions of periacinar
stromal thickening in transgenic mice. Panel H. A significant elevation in general fibroplasia is noted in transgenic mice over one year of age as
compared to age-matched wildtype controls and transgenic mice under one year of age (* P,0.05). Images A–F captured at6200 magnification and
image G at 6400.
doi:10.1371/journal.pone.0013751.g005
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prostate cancer and benign prostatic hyperplasia are associated
with elevated inflammation and both exhibit overexpression of
TGF-b1 in epithelial cells [3,4]. Data here is also consistent with
the chemokine function of TGF-b1 in recruitment of monocyte/
macrophages, however our data shows that recruited cells were
primarily monocytes and not mature macrophages. These data
would support the concept that TGF-b1 functions primarily to
recruit monocyte cell populations but limit their maturation to
macrophages. The significance of this tropism for nerve ganglia
and how it may affect prostate gland function is not yet
understood. Although previous studies using a xenograft tissue
recombination model have shown that overexpression of TGF-b1
induced an increased density of phenotypically distinct nerve
‘‘ganglion-like cells’’ [26], the potential role of prostate ganglia
inflammation in reactive stroma induction of this transgenic model
is not yet understood.
The function of the collagenous micronodules reported here has
not been elucidated. One interpretation is that these micronodules
evolve as a component of wound repair to induce a collapse of the
epithelial acini in damaged, non-functional glands in order to
effectively take these acini off-line as a compensatory response.
Closure of damaged acini might prevent retrograde introduction
of pathogens from the downstream urogenital tract into the
prostate gland stroma that houses vessels. Accordingly, in
conjunction with the other induced inflammatory responses in
vessels and nerves, these nodules may form to ostensibly sequester
or limit a potential nidus of infection from spreading in a prostate
gland with damaged prostatic acini and epithelial walls with
breached integrity. Indeed, these lesions are nearly identical in
histopathology to collagenous micronodules associated with
human prostate cancer [27], however the function of these
nodules has not yet been reported. Furthermore, we have observed
similar lesions associated with prostate carcinoma in the Hi-Myc
transgenic mouse model (data not shown). Accordingly, we
propose here that these nodules form and function as a key
component of adaptive homeostasis in glandular tissue to protect
from further damage and to promote repair.
The generation of focal fibroplasia, inflammation and collag-
enous micronodules in the stromal microenvironment of TGF-b1
overexpressing mice is consistent with the role of reactive in wound
repair biology [1,2,28]. These important adaptive responses
whereby fibrosis and inflammation act in coordinate manners
may provide additional insight into the tumor promoting nature of
the reactive stroma microenvironment observed in most carcino-
mas [3]. Overexpression of TGF-b1 in other murine epithelial
organ systems produces fibrotic responses, albeit somewhat
different from what we report here, since inflammation of ganglia
and the induction of collagenous micronodules have not been
reported previously [13,14,16]. Understanding these responses
Figure 6. Recruitment of immature myeloid cells to parasympathetic ganglia is increased in TGF-b1 transgenic mice. Panels A and B.
Inflammatory lesions demonstrate significantly greater recruitment of CD115+ myeloid cells to parasympathetic neurovascular bundles in transgenic
mice (Panel B) compared to wildtype control (Panel A). Panels C and D. Quantitation yields significantly greater CD115+ monocytes in transgenic
compared to wildtype parasympathetic ganglia in mice over one year of age (* P,0.05) (Panel C), whereas no significant differences in F4/80 staining
is observed (Panel D). All images captured at 6200.
doi:10.1371/journal.pone.0013751.g006
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targets for disorders where the stromal microenvironment plays a
pivotal role in progression and clinical outcome. Crosses of this
HA-TGF-b1(a) mouse into other transgenic backgrounds or use in
other experimental conditions may aid in studies of how
inflammation and reactive stroma in the microenvironment affects
benign, neoplastic, or inflammatory prostate diseases. Further
insight into downstream pathways of TGF-b1 and mechanisms in
prostate tissue homeostasis is important for understanding the role
of this factor in prostate disease progression.
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